We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
+37.14%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
–
AUM
$603M
AUM Growth
+$31.5M
Cap. Flow
-$94.5M
Cap. Flow %
-15.67%
Top 10 Hldgs %
66.11%
Holding
33
New
5
Increased
10
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$19.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$14.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$14.1M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$11.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$7.21M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$22.6M
2
TERN
Terns Pharmaceuticals
TERN
+$21.7M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.8M
4
PRCT icon
Procept Biorobotics
PRCT
+$12.1M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$8.51M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
2 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$54.3B
$70.9M 11.75%
76,417
+81
+0.1% +$66.8K
ICLR icon
2
Icon
ICLR
$12.7B
$53.5M 8.87%
308,143
-50,357
-14% -$6.41M
GH icon
3
Guardant Health
GH
$22.7B
$45.1M 7.48%
300,685
-9,596
-3% -$1.04M
INSM icon
4
Insmed
INSM
$28.9B
$41M 6.79%
384,130
+159,859
+71% +$19.4M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$13.4B
$35.7M 5.92%
624,676
+118,867
+24% +$6.51M
ILMN icon
6
Illumina
ILMN
$28.9B
$33M 5.46%
187,413
– –
SRRK icon
7
Scholar Rock
SRRK
$6.2B
$30.5M 5.06%
555,272
+61,253
+12% +$2.96M
PTGX icon
8
Protagonist Therapeutics
PTGX
$9.57B
$30.4M 5.05%
248,322
+69,000
+38% +$7.21M
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.64B
$29.5M 4.89%
884,121
– –
CMPS
10
Compass Pathways
CMPS
$1.77B
$29.2M 4.83%
2,060,427
– –
ASND icon
11
Ascendis Pharma A/S
ASND
$16.5B
$28.3M 4.69%
106,158
+19,508
+23% +$4.56M
RVMD icon
12
Revolution Medicines
RVMD
$44.1B
$22.5M 3.74%
120,346
+882
+0.7% +$129K
FTRE icon
13
Fortrea Holdings
FTRE
$1.79B
$20.6M 3.41%
1,181,274
-126,286
-10% -$1.7M
KYMR icon
14
Kymera Therapeutics
KYMR
$8.9B
$19.1M 3.16%
166,148
+20,332
+14% +$1.75M
AXSM icon
15
Axsome Therapeutics
AXSM
$11.4B
$15.9M 2.64%
+65,051
New +$14.1M
BSX icon
16
Boston Scientific
BSX
$73.5B
$15.8M 2.61%
369,164
+76,012
+26% +$4.13M
ALKS icon
17
Alkermes
ALKS
$8.26B
$15.6M 2.58%
297,302
+58,629
+25% +$2.29M
IONS icon
18
Ionis Pharmaceuticals
IONS
$9.51B
$15.4M 2.56%
+194,577
New +$14.6M
TEM
19
Tempus AI
TEM
$9.98B
$14.8M 2.46%
256,269
– –
DNTH icon
20
Dianthus Therapeutics
DNTH
$6.09B
$12.8M 2.12%
+131,344
New +$11.5M
ATAI icon
21
AtaiBeckley Inc
ATAI
$2.68B
$9.01M 1.49%
1,709,359
– –
AVTX icon
22
Avalo Therapeutics
AVTX
$1.04B
$4.34M 0.72%
+235,093
New +$3.72M
NTRA icon
23
Natera
NTRA
$45.5B
$4.3M 0.71%
15,847
-106,030
-87% -$22.6M
LLY icon
24
Eli Lilly
LLY
$1.09T
$2.39M 0.4%
+1,994
New +$2.04M
ISRG icon
25
Intuitive Surgical
ISRG
$138B
$1.75M 0.29%
4,390
– –
1
2

Similar funds

PIFP
Partners in Financial Planning Salem, Virginia $603M AUM 12.72% 1-Year Est. Return
IECM
Intrinsic Edge Capital Management Chicago, Illinois $603M AUM 66.97% 1-Year Est. Return
ERWM
Elk River Wealth Management Denver, Colorado $602M AUM 22.77% 1-Year Est. Return
CIG
Capricorn Investment Group Palo Alto, California $602M AUM 165.22% 1-Year Est. Return
JHCP
Jackson Hole Capital Partners Tulsa, Oklahoma $605M AUM 22.77% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
OCAM
Onex Canada Asset Management Toronto, Ontario, Canada $601M AUM 15.16% 1-Year Est. Return

Eagle Health Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Eagle Health Investments held 33 positions worth $603M, up 5.5% from $572M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eagle Health Investments withdrew a net $94.5M in Q2 2026, closing 6 positions and reducing 4 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $21.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 83% a quarter earlier, followed by Financials.

Against the trend, Eagle Health Investments opened a new position in Ionis Pharmaceuticals worth $15.4M.

  • Eagle Health Investments's largest Q2 2026 buy was Ionis Pharmaceuticals: 194,577 shares worth $15.4M.
  • Eagle Health Investments added most to Insmed in Q2 2026, an estimated $19.4M increase.
  • Eagle Health Investments's biggest Q2 2026 reduction was Natera, cutting an estimated $22.6M.
  • Eagle Health Investments fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $21.7M.
  • Eagle Health Investments's ten largest holdings make up 66% of its $603M portfolio in Q2 2026.
  • Eagle Health Investments opened 5 new positions and closed 6 in Q2 2026.
  • Eagle Health Investments's portfolio value rose 5.5% quarter-over-quarter to $603M.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.